<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Recent Healthcare IPOs | Statmint</title>
  <meta name="description" content="Track recent and upcoming healthcare and biotech IPOs with clear data and professional insights.">
  <link rel="icon" href="statmint_logo.jpeg" type="image/jpeg" />
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet"/>
  <link href="https://unpkg.com/aos@2.3.4/dist/aos.css" rel="stylesheet"/>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600&display=swap" rel="stylesheet"/>
  <link href="styles.css" rel="stylesheet" />
  <style>
    .hero {
      background: linear-gradient(rgba(0,0,0,0.6), rgba(0,0,0,0.6)),
                  url('index-hero.jpg') center/cover no-repeat;
      color: #fff;
      text-align: center;
      padding: 7rem 2rem;
    }

    .hero h1 {
      font-size: 3rem;
      font-weight: 700;
      margin-bottom: 0.5rem;
    }

    .hero p {
      max-width: 800px;
      margin: 0 auto;
      font-size: 1.2rem;
      color: #dee2e6;
    }
  </style>
</head>
<body>

  <!-- ✅ Header -->
  <header>
    <a href="index.html"><img src="statmint_logo.jpeg" alt="Statmint Logo"></a>
    <nav>
      <a href="index.html">Home</a>
      <a href="stocks.html">Healthcare Stocks</a>
      <a href="fda.html">FDA Approvals</a>
      <a href="ipos.html">Initial Public Offerings</a>
    </nav>
  </header>

  <!-- ✅ Hero -->
  <section class="hero" data-aos="fade-zoom-in">
    <h1 data-aos="fade-down">Recent Healthcare IPOs</h1>
    <p data-aos="fade-up">Track newly listed healthcare and biotech companies, their IPO performance, and market focus — all in one place.</p>
  </section>

  <!-- ✅ IPO Table -->
  <section class="section">
    <div class="container">
      <div class="table-responsive" data-aos="fade-up" data-aos-delay="100">
        <table class="table">
          <thead>
            <tr>
              <th>Company</th>
              <th>Ticker</th>
              <th>IPO Date</th>
              <th>Amount Raised</th>
              <th>Focus Area</th>
              <th>Summary</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><a href="https://www.genecure.com" target="_blank">GeneCure Therapeutics</a></td>
              <td>GNCR</td>
              <td>January 18, 2025</td>
              <td>$180M</td>
              <td>Rare Genetic Diseases</td>
              <td>IPO proceeds fund next-gen gene therapies for ultra-rare disorders with no approved treatments.</td>
            </tr>
            <tr>
              <td><a href="https://www.onconova.com" target="_blank">OncoNova Bio</a></td>
              <td>ONVB</td>
              <td>February 25, 2025</td>
              <td>$250M</td>
              <td>Oncology</td>
              <td>Developer of targeted small molecules for resistant solid tumors, expanding Phase II trials post-IPO.</td>
            </tr>
            <tr>
              <td><a href="https://www.immunonext.com" target="_blank">ImmunoNext Inc.</a></td>
              <td>IMNX</td>
              <td>March 10, 2025</td>
              <td>$300M</td>
              <td>Immuno-oncology</td>
              <td>Emerging player in T-cell therapies for difficult-to-treat cancers, using novel bispecific antibodies.</td>
            </tr>
            <tr>
              <td><a href="https://neurosparkhealth.com" target="_blank">NeuroSpark Health</a></td>
              <td>NSPK</td>
              <td>April 5, 2025</td>
              <td>$120M</td>
              <td>Neurology</td>
              <td>Focused on neurodegenerative diseases, advancing a lead compound for ALS and Parkinson’s symptoms.</td>
            </tr>
            <tr>
              <td><a href="https://www.cardionova.com" target="_blank">CardioNova</a></td>
              <td>CDNV</td>
              <td>May 22, 2025</td>
              <td>$200M</td>
              <td>Cardiology</td>
              <td>Developing RNA-based treatments for heart failure and other chronic cardiovascular conditions.</td>
            </tr>
            <!-- Add more rows as real IPOs occur -->
          </tbody>
        </table>
      </div>
    </div>
  </section>

  <!-- ✅ Footer -->
  <footer>
    <div class="container">
      <p>© 2025 Statmint. IPO data sourced from company filings and financial news. For reference only.</p>
      <p>Questions? <a href="mailto:info@statmint.org">Contact us</a></p>
    </div>
  </footer>

  <script src="https://unpkg.com/aos@2.3.4/dist/aos.js"></script>
  <script>
    AOS.init({
      duration: 1000,
      once: true,
      easing: 'ease-in-out'
    });
  </script>
</body>
</html>
